Featured Research

from universities, journals, and other organizations

Hepatotoxicity And Statins

Date:

June 1, 2005

Source:

John Wiley & Sons, Inc.

Summary:

Statins appear to be safe for people with fatty liver disease who could benefit from their cholesterol-lowering capabilities, concludes a review paper published in the April 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

Share This

Statins appear to be safe for people with fatty liver disease who could benefit from their cholesterol-lowering capabilities, concludes a review paper published in the April 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., the journal is available online via Wiley InterScience at www.interscience.wiley.com/journal/hepatology.

Related Articles

Statins are a class of drugs that lower cholesterol levels by inhibiting the liver's production of cholesterol. They have been shown to decrease the risk of artherosclerosis and related diseases. In the United States, doctors write millions of prescriptions for statins each year. However, commonly, patients on statins have elevations of liver enzymes. Current statin product packaging recommends monitoring patients' liver values over the course of their usage. This recommendation may concern physicians whose patients also have known liver conditions, including elevated, though asymptomatic, liver enzymes.

Naga Chalasani, M.D., of Indiana University School of Medicine, thoroughly examined the literature related to statin hepatotoxicity to better understand statins' effects on patients. Statins, especially in increasing doses, have been associated with asymptomatic elevation of aminotransferases, though this occurs in fewer than three percent of statin users. Notably, this outcome has also occurred with similar frequency in placebo-treated patients in clinical trials. This "raises the possibility that hyperlipidemic patients may have spontaneous fluctuations in transaminases whether or not they receive statins," Chalasani suggests. Still, there have been rare reports of significant liver injury associated with statins.

Statins are not recommended for patients with active liver disease, though the recommendations for those with nonalcoholic fatty liver disease (NAFLD) are unclear. This group of patients is important to consider because the disease is common in patients with high cholesterol and their liver condition may create a higher cardiovascular risk that could be addressed through statin therapy.

"The studies examining the safety of statins in patients with NAFLD are limited, but the existing data provide some evidence that they can be used safely," reports the author, whose own studies recently showed that hyperlipidemic patients with elevated baseline liver enzymes are not at a higher risk for hepatotoxicity from statins compared with hyperlipidemic patients with normal transaminases.

The relationship between statins and cancer raises another important question. Statins have been shown to cause various tumors in rodents, though short-term studies have revealed no carcinogenic effects in humans. Still other studies have suggested that statins have an anti-tumor effect. Additionally, rhabdomyolysis can be a complication of statin therapy and may be related to higher serum concentration levels of statins. Patients with decreased hepatic drug metabolizing activity due to cirrhosis or other liver ailments may have a higher risk of muscle disease from statins, although the association has not been studied.

Further studies should examine the long-term effect of statins on the liver in patients with NAFLD and non-alcoholic steatohepatitis. More research is also needed to investigate if patients with those diseases show any clinically relevant changes in the pharmacokinetics of different statins at various doses. Finally, the author suggests a reexamination of the product labeling on statins, which currently calls for monitoring of liver biochemistries before and during usage.

"It is now evident that elevated aminotransferases are insensitive to detect underlying hepatic steatosis and patients with advanced fibrosis and cirrhosis may have entirely normal aminotransferases," he reports.

After considering the available literature thoroughly, Dr. Chalasani concludes, "There is no sound rationale why statins should not be used in patients with chronic liver disease who otherwise need statin therapy."

Featured Research

Mar. 31, 2015  Researchers have illuminated an important distinction between mice and humans: how human livers heal. The difference centers on a protein called PPAR alpha which activates liver ... full story

Mar. 31, 2015  Researchers have recorded the first direct observations of the micro-scale mechanisms behind the ability of skin to resist tearing. The results could be applied to the improvement of artificial skin, ... full story

Mar. 31, 2015  Fewer than half of the physicians trained in the United States in 2013 received formal education or training on the subject of exercise, according to new research. "There are immense medical benefits ... full story

Mar. 31, 2015  Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug, researchers report. "With this treatment, cells under ... full story

Mar. 31, 2015  Increasing state alcohol taxes could prevent thousands of deaths a year from car crashes, say researchers, who found alcohol-related motor vehicle crashes decreased after taxes on beer, wine and ... full story

Mar. 31, 2015  Alcoholism takes a toll on every aspect of a person's life, including skin problems. Now, a new research report helps explain why this happens and what might be done to address it. "The clinical ... full story

Mar. 31, 2015  A new population of 'memory' immune cells has been discovered by scientists, throwing light on what the body does when it sees a microbe for the second time. This insight, and others like it, will ... full story

Mar. 31, 2015  Coronary heart disease and stroke, two of the leading causes of death in the United States, are diseases associated with heightened platelet reactivity. A new study in humans suggests an underlying ... full story

Mar. 31, 2015  A new study had researchers seeking answers to why the therapeutic benefit afforded by SSRIs was so limited in children and teenagers. If researchers can uncover the biological mechanisms preventing ... full story

Featured Videos

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015)  The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports.
Video provided by Reuters

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015)  Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline.
Video provided by Washington Post

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015)  Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17
Video provided by AFP

Sep. 10, 2013  A new analysis concludes that large numbers of patients in advanced stages of kidney disease are inappropriately being prescribed statins to lower their cholesterol -- drugs that offer them no ... full story

Aug. 29, 2013  Not only do statins extend lives by lowering cholesterol levels and reducing the risks of cardiovascular disease, but new research suggests that they may extend lifespans as well. Specifically, ... full story

June 7, 2012  A new study has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, and these changes may explain the ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.